Combination of fludarabine, amsacrine, and cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia

Comparable Analysis of Outcomes for Allogeneic Peripheral Blood Stem Cell Transplantation from Matched Related and Matched Unrelated Donors in Acute Myeloid Leukemia

(2011) Soo Jung Lee et al.   ACTA HAEMATOLOGICA

Intermediate intensity conditioning regimen containing FLAMSA, treosulfan, cyclophosphamide, and ATG for allogeneic stem cell transplantation in elderly patients with relapsed or high-risk acute myeloid leukemia

(2011) Jens Marcus Chemnitz et al.   ANNALS OF HEMATOLOGY

Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS

(2011) S M Luger et al.   BONE MARROW TRANSPLANTATION

The EBMT risk score

(2011) A Gratwohl   BONE MARROW TRANSPLANTATION

CD34+ cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies

(2010) S G Holtan et al.   BONE MARROW TRANSPLANTATION

Increasing hematopoietic microchimerism is a reliable indicator of incipient AML relapse

(2010) O. HORKY et al.   International Journal of Laboratory Hematology

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

(2009) H. Dohner et al.   BLOOD

The number of infused CD34+ cells does not influence the incidence of GVHD or the outcome of allogeneic PBSC transplantation, using reduced-intensity conditioning and antithymocyte globulin

(2009) P Tsirigotis et al.   BONE MARROW TRANSPLANTATION

Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009

(2009) P Ljungman et al.   BONE MARROW TRANSPLANTATION

Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial

(2009) Jürgen Finke et al.   LANCET ONCOLOGY

High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission

(2008) C Schmid et al.   BONE MARROW TRANSPLANTATION